Copyright Reports & Markets. All rights reserved.

Global Nuclear Drug for Therapeutic Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered: Ranking by Nuclear Drug for Therapeutic Revenue
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Nuclear Drug for Therapeutic Market Size Growth Rate by Type: 2020 VS 2026
      • 1.4.2 Radium-223
      • 1.4.3 Lutetium-177
      • 1.4.4 Iodine-131
      • 1.4.5 Other
    • 1.5 Market by Application
      • 1.5.1 Global Nuclear Drug for Therapeutic Market Share by Application: 2020 VS 2026
      • 1.5.2 Thyroid
      • 1.5.3 Bone Metastasis
      • 1.5.4 Lymphoma
      • 1.5.5 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends by Regions

    • 2.1 Nuclear Drug for Therapeutic Market Perspective (2015-2026)
    • 2.2 Nuclear Drug for Therapeutic Growth Trends by Regions
      • 2.2.1 Nuclear Drug for Therapeutic Market Size by Regions: 2015 VS 2020 VS 2026
      • 2.2.2 Nuclear Drug for Therapeutic Historic Market Share by Regions (2015-2020)
      • 2.2.3 Nuclear Drug for Therapeutic Forecasted Market Size by Regions (2021-2026)
    • 2.3 Industry Trends and Growth Strategy
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis
      • 2.3.5 Nuclear Drug for Therapeutic Market Growth Strategy
      • 2.3.6 Primary Interviews with Key Nuclear Drug for Therapeutic Players (Opinion Leaders)

    3 Competition Landscape by Key Players

    • 3.1 Global Top Nuclear Drug for Therapeutic Players by Market Size
      • 3.1.1 Global Top Nuclear Drug for Therapeutic Players by Revenue (2015-2020)
      • 3.1.2 Global Nuclear Drug for Therapeutic Revenue Market Share by Players (2015-2020)
      • 3.1.3 Global Nuclear Drug for Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 3.2 Global Nuclear Drug for Therapeutic Market Concentration Ratio
      • 3.2.1 Global Nuclear Drug for Therapeutic Market Concentration Ratio (CR5 and HHI)
      • 3.2.2 Global Top 10 and Top 5 Companies by Nuclear Drug for Therapeutic Revenue in 2019
    • 3.3 Nuclear Drug for Therapeutic Key Players Head office and Area Served
    • 3.4 Key Players Nuclear Drug for Therapeutic Product Solution and Service
    • 3.5 Date of Enter into Nuclear Drug for Therapeutic Market
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type (2015-2026)

    • 4.1 Global Nuclear Drug for Therapeutic Historic Market Size by Type (2015-2020)
    • 4.2 Global Nuclear Drug for Therapeutic Forecasted Market Size by Type (2021-2026)

    5 Nuclear Drug for Therapeutic Breakdown Data by Application (2015-2026)

    • 5.1 Global Nuclear Drug for Therapeutic Market Size by Application (2015-2020)
    • 5.2 Global Nuclear Drug for Therapeutic Forecasted Market Size by Application (2021-2026)

    6 North America

    • 6.1 North America Nuclear Drug for Therapeutic Market Size (2015-2020)
    • 6.2 Nuclear Drug for Therapeutic Key Players in North America (2019-2020)
    • 6.3 North America Nuclear Drug for Therapeutic Market Size by Type (2015-2020)
    • 6.4 North America Nuclear Drug for Therapeutic Market Size by Application (2015-2020)

    7 Europe

    • 7.1 Europe Nuclear Drug for Therapeutic Market Size (2015-2020)
    • 7.2 Nuclear Drug for Therapeutic Key Players in Europe (2019-2020)
    • 7.3 Europe Nuclear Drug for Therapeutic Market Size by Type (2015-2020)
    • 7.4 Europe Nuclear Drug for Therapeutic Market Size by Application (2015-2020)

    8 China

    • 8.1 China Nuclear Drug for Therapeutic Market Size (2015-2020)
    • 8.2 Nuclear Drug for Therapeutic Key Players in China (2019-2020)
    • 8.3 China Nuclear Drug for Therapeutic Market Size by Type (2015-2020)
    • 8.4 China Nuclear Drug for Therapeutic Market Size by Application (2015-2020)

    9 Japan

    • 9.1 Japan Nuclear Drug for Therapeutic Market Size (2015-2020)
    • 9.2 Nuclear Drug for Therapeutic Key Players in Japan (2019-2020)
    • 9.3 Japan Nuclear Drug for Therapeutic Market Size by Type (2015-2020)
    • 9.4 Japan Nuclear Drug for Therapeutic Market Size by Application (2015-2020)

    10 Southeast Asia

    • 10.1 Southeast Asia Nuclear Drug for Therapeutic Market Size (2015-2020)
    • 10.2 Nuclear Drug for Therapeutic Key Players in Southeast Asia (2019-2020)
    • 10.3 Southeast Asia Nuclear Drug for Therapeutic Market Size by Type (2015-2020)
    • 10.4 Southeast Asia Nuclear Drug for Therapeutic Market Size by Application (2015-2020)

    11 India

    • 11.1 India Nuclear Drug for Therapeutic Market Size (2015-2020)
    • 11.2 Nuclear Drug for Therapeutic Key Players in India (2019-2020)
    • 11.3 India Nuclear Drug for Therapeutic Market Size by Type (2015-2020)
    • 11.4 India Nuclear Drug for Therapeutic Market Size by Application (2015-2020)

    12 Central & South America

    • 12.1 Central & South America Nuclear Drug for Therapeutic Market Size (2015-2020)
    • 12.2 Nuclear Drug for Therapeutic Key Players in Central & South America (2019-2020)
    • 12.3 Central & South America Nuclear Drug for Therapeutic Market Size by Type (2015-2020)
    • 12.4 Central & South America Nuclear Drug for Therapeutic Market Size by Application (2015-2020)

    13 Key Players Profiles

    • 13.1 Bayer
      • 13.1.1 Bayer Company Details
      • 13.1.2 Bayer Business Overview and Its Total Revenue
      • 13.1.3 Bayer Nuclear Drug for Therapeutic Introduction
      • 13.1.4 Bayer Revenue in Nuclear Drug for Therapeutic Business (2015-2020))
      • 13.1.5 Bayer Recent Development
    • 13.2 Novartis
      • 13.2.1 Novartis Company Details
      • 13.2.2 Novartis Business Overview and Its Total Revenue
      • 13.2.3 Novartis Nuclear Drug for Therapeutic Introduction
      • 13.2.4 Novartis Revenue in Nuclear Drug for Therapeutic Business (2015-2020)
      • 13.2.5 Novartis Recent Development
    • 13.3 China Isotope & Radiation
      • 13.3.1 China Isotope & Radiation Company Details
      • 13.3.2 China Isotope & Radiation Business Overview and Its Total Revenue
      • 13.3.3 China Isotope & Radiation Nuclear Drug for Therapeutic Introduction
      • 13.3.4 China Isotope & Radiation Revenue in Nuclear Drug for Therapeutic Business (2015-2020)
      • 13.3.5 China Isotope & Radiation Recent Development
    • 13.4 Dongcheng
      • 13.4.1 Dongcheng Company Details
      • 13.4.2 Dongcheng Business Overview and Its Total Revenue
      • 13.4.3 Dongcheng Nuclear Drug for Therapeutic Introduction
      • 13.4.4 Dongcheng Revenue in Nuclear Drug for Therapeutic Business (2015-2020)
      • 13.4.5 Dongcheng Recent Development
    • 13.5 Q BioMed
      • 13.5.1 Q BioMed Company Details
      • 13.5.2 Q BioMed Business Overview and Its Total Revenue
      • 13.5.3 Q BioMed Nuclear Drug for Therapeutic Introduction
      • 13.5.4 Q BioMed Revenue in Nuclear Drug for Therapeutic Business (2015-2020)
      • 13.5.5 Q BioMed Recent Development
    • 13.6 Curium Pharmaceuticals
      • 13.6.1 Curium Pharmaceuticals Company Details
      • 13.6.2 Curium Pharmaceuticals Business Overview and Its Total Revenue
      • 13.6.3 Curium Pharmaceuticals Nuclear Drug for Therapeutic Introduction
      • 13.6.4 Curium Pharmaceuticals Revenue in Nuclear Drug for Therapeutic Business (2015-2020)
      • 13.6.5 Curium Pharmaceuticals Recent Development
    • 13.7 Jubilant DraxImage
      • 13.7.1 Jubilant DraxImage Company Details
      • 13.7.2 Jubilant DraxImage Business Overview and Its Total Revenue
      • 13.7.3 Jubilant DraxImage Nuclear Drug for Therapeutic Introduction
      • 13.7.4 Jubilant DraxImage Revenue in Nuclear Drug for Therapeutic Business (2015-2020)
      • 13.7.5 Jubilant DraxImage Recent Development
    • 13.8 Lantheus
      • 13.8.1 Lantheus Company Details
      • 13.8.2 Lantheus Business Overview and Its Total Revenue
      • 13.8.3 Lantheus Nuclear Drug for Therapeutic Introduction
      • 13.8.4 Lantheus Revenue in Nuclear Drug for Therapeutic Business (2015-2020)
      • 13.8.5 Lantheus Recent Development
    • 13.9 Spectrum Pharmaceuticals
      • 13.9.1 Spectrum Pharmaceuticals Company Details
      • 13.9.2 Spectrum Pharmaceuticals Business Overview and Its Total Revenue
      • 13.9.3 Spectrum Pharmaceuticals Nuclear Drug for Therapeutic Introduction
      • 13.9.4 Spectrum Pharmaceuticals Revenue in Nuclear Drug for Therapeutic Business (2015-2020)
      • 13.9.5 Spectrum Pharmaceuticals Recent Development
    • 13.10 Progenics Pharmaceuticals
      • 13.10.1 Progenics Pharmaceuticals Company Details
      • 13.10.2 Progenics Pharmaceuticals Business Overview and Its Total Revenue
      • 13.10.3 Progenics Pharmaceuticals Nuclear Drug for Therapeutic Introduction
      • 13.10.4 Progenics Pharmaceuticals Revenue in Nuclear Drug for Therapeutic Business (2015-2020)
      • 13.10.5 Progenics Pharmaceuticals Recent Development
    • 13.11 International Isotopes
      • 10.11.1 International Isotopes Company Details
      • 10.11.2 International Isotopes Business Overview and Its Total Revenue
      • 10.11.3 International Isotopes Nuclear Drug for Therapeutic Introduction
      • 10.11.4 International Isotopes Revenue in Nuclear Drug for Therapeutic Business (2015-2020)
      • 10.11.5 International Isotopes Recent Development

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
        • 15.1.2 Data Source
      • 15.2 Disclaimer

      This report focuses on the global Nuclear Drug for Therapeutic status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Nuclear Drug for Therapeutic development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Bayer
      Novartis
      China Isotope & Radiation
      Dongcheng
      Q BioMed
      Curium Pharmaceuticals
      Jubilant DraxImage
      Lantheus
      Spectrum Pharmaceuticals
      Progenics Pharmaceuticals
      International Isotopes

      Market segment by Type, the product can be split into
      Radium-223
      Lutetium-177
      Iodine-131
      Other
      Market segment by Application, split into
      Thyroid
      Bone Metastasis
      Lymphoma
      Other

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Nuclear Drug for Therapeutic status, future forecast, growth opportunity, key market and key players.
      To present the Nuclear Drug for Therapeutic development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by type, market and key regions.

      In this study, the years considered to estimate the market size of Nuclear Drug for Therapeutic are as follows:
      History Year: 2015-2019
      Base Year: 2019
      Estimated Year: 2020
      Forecast Year 2020 to 2026
      For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now